EGFR and non-small cell lung carcinoma: (5) reported that in patients still living with advanced EGFR-mutated NSCLC, BM incidence increased over time: 34.2% at 1 year, 38.4% at 2 years, 46.7% at 3 years, 48.7% at 4 years, and 52.9% at 5 years.